Phase 4 N=894 Long-Acting Reversible Contraception
Contraception
Primary: Contraceptive Method Discontinuation — 300; 62; 142 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=2,885 Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study
Contraception
Primary: Pearl Index up to 3 Years — 0.33; 0.31 Pregnancies per 100 women years
N/A N=102 Postplacental or Delayed Insertion of the Levonorgestrel-releasing Intrauterine Device (IUD) After Vaginal Delivery
Contraception
Primary: IUD Usage Rate at 6 Months — 43; 39 participants
Phase 2 N=286 Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception
Contraception
Primary: The Primary Outcome Measure is Effectiveness as Calculated by the Pearl Index — 0.53; 1.41; 0.00 Pearl Index
N/A N=240 Video Versus Conversational Contraceptive Counseling During Maternity Hospitalization
Contraceptive Usage · Contraception Behavior
Primary: Total Counseling Time — 16.8; 16.3 minutes
N/A N=1,008 Innovative Model of Patient-Centered ConTraception
Contraception · Unintended Pregnancy
Primary: Unintended Pregnancy — 46; 25 Participants
N/A N=274 Levonorgestrel Intrauterine System For Emergency Contraception
Pregnancy, Unplanned · Pregnancy; Accident
Primary: Number of Participants With Pregnancy Following Emergency Contraception — 0; 0; 0; 6 Participants
N/A N=58,303 Long-term Active Surveillance Study for Oral Contraceptives (LASS)
Arterial Thromboembolism · Venous Thromboembolism · Breast Cancer
Primary: Arterial Thromboembolism — 7; 22; 34 participants
Phase 4 N=711 RAPID EC - Rct Assessing Pregnancy With Intrauterine Devices for EC
Contraception
Primary: Percentage of Participants Reporting a Pregnancy — 0; 0.3 % of participants reporting pregnancy
N/A N=75 Study of the Implementation of Telehealth-Supported LARC Provision in School-Based Health Centers
Long Acting Reversible Contraception · Contraception Behavior
Primary: Number of Telehealth and Non-Telehealth LARC Device Initiations Within the SBHC Network — 4; 73 device initiations
Phase 4 N=50 LNG-IUS at 2 Weeks Postpartum
Contraception · Malposition of Intrauterine Contraceptive Device
Primary: Number of Participants Who Would Recommend the LNG-IUS to a Friend at 6-months Postpartum. — 40 Participants
Phase 3 N=65 Intervention to End Recurrent Unscheduled Bleeding Trial
Contraception · Bleeding
Primary: Number of Bleeding/Spotting Days With Use of Ulipristal Acetate as Measured by Daily Bleeding Diaries — 7; 12 days — p=0.002
N/A N=29 Mirena Intrauterine System Timing of Insertion: A Randomized Controlled Trial
Postpartum Period
Primary: Mirena in Place — 10; 3 participants
Phase 3 N=394 Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).
Menopause
Primary: Number of Bleeding Days — 0; 0; 0; 0 Bleeding days — p=0.128
Phase 4 N=88 'Levonorgestrel IUD Insertion After D&E Procedure
Contraceptive Usage
Primary: The Primary Outcome is LNG-IUD Usage Six Months Following Enrollment. — 85.2; 62.9 percentage of participants — p=0.05
Phase 3 N=95 Labor and Delivery Implant Insertion: A Randomized Controlled Trial
Postpartum Contraception · Family Planning
Primary: Time to Lactogenesis Stage II [Questionnaire] — 65; 67.5 hours
Phase 4 N=69 Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant
Complications; Contraceptive · Female Lactation
Primary: Time to Lactogenesis Stage II — 64.3; 65.2 hours — p=<0.05
Phase 4 N=35 Postpartum Levonorgestrel-releasing Intrauterine System and Breastfeeding
Postpartum Contraception
Primary: Breastfeeding — 10; 9 participants
N/A N=123 Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study
Contraception
Primary: IUD Expulsion Rate — 20; 7 Participants
Phase 3 N=72 Pericoital Oral Contraception With Levonorgestrel
Healthy
Primary: Efficacy: the Pearl Index (Number of Pregnancies Per 100 Woman-years) in the Primary Evaluable Population (18-35) — 22.4 pregnancies per 100 woman years
Phase 2 N=742 Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)
Contraception
Primary: Pearl Index — 0.17; 0.82; 0.00 Number per 100 women years
Phase 3 N=567 LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study
Contraception
Primary: Overall Satisfaction Rate at 18 Months (Last Observation Carried Forward, LOCF) — 82.1; 81.9 Percentage of participants
Phase 4 N=24 Rifampin and the Contraceptive Implant
Contraception · Tuberculosis
Primary: Serum Etonogestrel Concentrations — 164.0; 47.8 pg/mL
N/A N=57 Copper T380 IUD Versus Oral Levonorgestrel for Emergency Contraception vs. Plan B for Emergency Contraception
Pregnancy
Primary: Use of an Effective Method of Contraception at 6 Months After Requesting Emergency Contraception — 9; 13 participants
Phase 4 N=96 Postpartum Etonogestrel Implant for Adolescents
Adolescence · Contraception · Postpartum
Primary: Continuation at 1 Year — 21; 30 participants
Phase 4 N=285 BLIS - Breastfeeding Levonorgestrel IUD Study
Contraception
Primary: Breastfeeding Continuation Rates at 8 Weeks Postpartum — 88; 86 Participants
N/A N=321 A Comparison of Continuation Rates for Three Hormonal Contraceptive Methods
Contraception
Primary: Continuation Rates — 82; 78; 83 participants
Phase 3 N=1,384 AMP002 Phase III Contraceptive Study
Contraception
Primary: Number of Subjects With Pregnancy Outcomes to Measure Contraceptive Efficacy — 100 Participants
N/A N=199 Comparison of Two Intrauterine Devices (IUDs) Among Cape Town HIV-positive Women
HIV
Primary: Participants With Detectable Genital Tract HIV Ribonucleic Acid (RNA) Viral Load (VL) — 18; 23; 10; 7 Participants — p=0.66
N/A N=9 Left Atrial Appendage Closure With SentreHeart Lariat® Device
Cardioembolic Stroke · Atrial Fibrillation
Primary: Number of Participants With Successful Stand-Alone Left Atrial Appendage Closure Using SentreHeart Lariat Device as Measured by Left Atrial Appendage Closure Rates — 6…